• Je něco špatně v tomto záznamu ?

Amiridine-piperazine hybrids as cholinesterase inhibitors and potential multitarget agents for Alzheimer's disease treatment

GF. Makhaeva, SV. Lushchekina, NV. Kovaleva, T. Yu Astakhova, NP. Boltneva, EV. Rudakova, OG. Serebryakova, AN. Proshin, IV. Serkov, TP. Trofimova, VA. Tafeenko, EV. Radchenko, VA. Palyulin, VP. Fisenko, J. Korábečný, O. Soukup, RJ. Richardson

. 2021 ; 112 (-) : 104974. [pub] 20210521

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23004981

We synthesized eleven new amiridine-piperazine hybrids 5a-j and 7 as potential multifunctional agents for Alzheimer's disease (AD) treatment by reacting N-chloroacetylamiridine with piperazines. The compounds displayed mixed-type reversible inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Conjugates were moderate inhibitors of equine and human BChE with negligible fluctuation in anti-BChE activity, whereas anti-AChE activity was substantially dependent on N4-substitution of the piperazine ring. Compounds with para-substituted aromatic moieties (5g, 5h, and bis-amiridine 7) had the highest anti-AChE activity in the low micromolar range. Top-ranked compound 5h, N-(2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-yl)-2-[4-(4-nitro-phenyl)-piperazin-1-yl]-acetamide, had an IC50 for AChE = 1.83 ± 0.03 μM (Ki = 1.50 ± 0.12 and αKi = 2.58 ± 0.23 μM). The conjugates possessed low activity against carboxylesterase, indicating a likely absence of unwanted drug-drug interactions in clinical use. In agreement with analysis of inhibition kinetics and molecular modeling studies, the lead compounds were found to bind effectively to the peripheral anionic site of AChE and displace propidium, indicating their potential to block AChE-induced β-amyloid aggregation. Similar propidium displacement activity was first shown for amiridine. Two compounds, 5c (R = cyclohexyl) and 5e (R = 2-MeO-Ph), exhibited appreciable antioxidant capability with Trolox equivalent antioxidant capacity values of 0.47 ± 0.03 and 0.39 ± 0.02, respectively. Molecular docking and molecular dynamics simulations provided insights into the structure-activity relationships for AChE and BChE inhibition, including the observation that inhibitory potencies and computed pKa values of hybrids were generally lower than those of the parent molecules. Predicted ADMET and physicochemical properties of conjugates indicated good CNS bioavailability and safety parameters comparable to those of amiridine and therefore acceptable for potential lead compounds at the early stages of anti-AD drug development.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23004981
003      
CZ-PrNML
005      
20230425171831.0
007      
ta
008      
230418s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.bioorg.2021.104974 $2 doi
035    __
$a (PubMed)34029971
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Makhaeva, Galina F $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia
245    10
$a Amiridine-piperazine hybrids as cholinesterase inhibitors and potential multitarget agents for Alzheimer's disease treatment / $c GF. Makhaeva, SV. Lushchekina, NV. Kovaleva, T. Yu Astakhova, NP. Boltneva, EV. Rudakova, OG. Serebryakova, AN. Proshin, IV. Serkov, TP. Trofimova, VA. Tafeenko, EV. Radchenko, VA. Palyulin, VP. Fisenko, J. Korábečný, O. Soukup, RJ. Richardson
520    9_
$a We synthesized eleven new amiridine-piperazine hybrids 5a-j and 7 as potential multifunctional agents for Alzheimer's disease (AD) treatment by reacting N-chloroacetylamiridine with piperazines. The compounds displayed mixed-type reversible inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE). Conjugates were moderate inhibitors of equine and human BChE with negligible fluctuation in anti-BChE activity, whereas anti-AChE activity was substantially dependent on N4-substitution of the piperazine ring. Compounds with para-substituted aromatic moieties (5g, 5h, and bis-amiridine 7) had the highest anti-AChE activity in the low micromolar range. Top-ranked compound 5h, N-(2,3,5,6,7,8-hexahydro-1H-cyclopenta[b]quinolin-9-yl)-2-[4-(4-nitro-phenyl)-piperazin-1-yl]-acetamide, had an IC50 for AChE = 1.83 ± 0.03 μM (Ki = 1.50 ± 0.12 and αKi = 2.58 ± 0.23 μM). The conjugates possessed low activity against carboxylesterase, indicating a likely absence of unwanted drug-drug interactions in clinical use. In agreement with analysis of inhibition kinetics and molecular modeling studies, the lead compounds were found to bind effectively to the peripheral anionic site of AChE and displace propidium, indicating their potential to block AChE-induced β-amyloid aggregation. Similar propidium displacement activity was first shown for amiridine. Two compounds, 5c (R = cyclohexyl) and 5e (R = 2-MeO-Ph), exhibited appreciable antioxidant capability with Trolox equivalent antioxidant capacity values of 0.47 ± 0.03 and 0.39 ± 0.02, respectively. Molecular docking and molecular dynamics simulations provided insights into the structure-activity relationships for AChE and BChE inhibition, including the observation that inhibitory potencies and computed pKa values of hybrids were generally lower than those of the parent molecules. Predicted ADMET and physicochemical properties of conjugates indicated good CNS bioavailability and safety parameters comparable to those of amiridine and therefore acceptable for potential lead compounds at the early stages of anti-AD drug development.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a Alzheimerova nemoc $x farmakoterapie $x metabolismus $7 D000544
650    _2
$a aminochinoliny $x chemie $x farmakologie $7 D000634
650    _2
$a zvířata $7 D000818
650    _2
$a antioxidancia $x chemická syntéza $x chemie $x farmakologie $7 D000975
650    _2
$a benzothiazoly $x antagonisté a inhibitory $7 D052160
650    _2
$a butyrylcholinesterasa $x metabolismus $7 D002091
650    _2
$a cholinesterasové inhibitory $x chemická syntéza $x chemie $x farmakologie $7 D002800
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a koně $7 D006736
650    _2
$a lidé $7 D006801
650    _2
$a molekulární modely $7 D008958
650    _2
$a molekulární struktura $7 D015394
650    _2
$a neuroprotektivní látky $x chemická syntéza $x chemie $x farmakologie $7 D018696
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a piperazin $x chemie $x farmakologie $7 D000077489
650    _2
$a vztahy mezi strukturou a aktivitou $7 D013329
650    _2
$a kyseliny sulfonové $x antagonisté a inhibitory $7 D013451
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lushchekina, Sofya V $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia; Emanuel Institute of Biochemical Physics Russian Academy of Sciences, Moscow 119334, Russia
700    1_
$a Kovaleva, Nadezhda V $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia
700    1_
$a Yu Astakhova, Tatiana $u Emanuel Institute of Biochemical Physics Russian Academy of Sciences, Moscow 119334, Russia
700    1_
$a Boltneva, Natalia P $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia
700    1_
$a Rudakova, Elena V $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia
700    1_
$a Serebryakova, Olga G $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia
700    1_
$a Proshin, Alexey N $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia
700    1_
$a Serkov, Igor V $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia
700    1_
$a Trofimova, Tatiana P $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia; Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
700    1_
$a Tafeenko, Victor A $u Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
700    1_
$a Radchenko, Eugene V $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia; Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
700    1_
$a Palyulin, Vladimir A $u Institute of Physiologically Active Compounds Russian Academy of Sciences, Chernogolovka 142432, Russia; Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia
700    1_
$a Fisenko, Vladimir P $u I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119881, Russia
700    1_
$a Korábečný, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, 500 05 Hradec Kralove, Czech Republic
700    1_
$a Richardson, Rudy J $u Department of Environmental Health Sciences, University of Michigan, Ann Arbor, MI 48109 USA; Department of Neurology, University of Michigan, Ann Arbor, MI 48109 USA; Center of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI 48109 USA. Electronic address: rjrich@umich.edu
773    0_
$w MED00000771 $t Bioorganic chemistry $x 1090-2120 $g Roč. 112, č. - (2021), s. 104974
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34029971 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425171827 $b ABA008
999    __
$a ok $b bmc $g 1925212 $s 1191190
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2021 $b 112 $c - $d 104974 $e 20210521 $i 1090-2120 $m Bioorganic chemistry $n Bioorg Chem $x MED00000771
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace